Pipeline Discoveries for Autoimmune Diseases and Chronic Inflammation
Inflammation Immunology Drug Pipeline & Clinical Trials
Pfizer's mission is to deliver medicines that make a real difference in quality of life for patients with autoimmune diseases and chronic inflammation. Scientists in our research and development (R&D) programs are committed to speeding the delivery of new treatments. We pledge to maintain the safety of patients who take part in our trials and to uphold the highest ethical standards in all of our research initiatives.
On this page, you will find more information about our pipeline, which investigational therapies are under development, and in which stages.
If you are a Health Care Professional and interested in further details (including pathways being explored, mechanisms of action of investigational compounds, and an overall summary of investigational compounds organized by therapy area and disease state), please visit our in-depth Pfizer Immunology & Inflammation Research Pipeline site.
Inflammation Immunology Pipeline & Trials
Immunology Pipeline as of July 28, 2021
- Discovery Projects
- 3Phase 1
- 16Phase 2
- 1Phase 3
- 2Registration
- Total22
| Compound Name | Indication | Phase | Submission Type | Compound Type |
|---|---|---|---|---|
abrocitinib (PF-04965842) Therapeutic Area: Inflammation & Immunology Phase:Registration Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: JAK1 Inhibitor | Atopic Dermatitis (PRIORITY REVIEW, BREAKTHROUGH - U.S., E.U.) | Registration | New Molecular Entity | Small Molecule |
Xeljanz (tofacitinib) Therapeutic Area: Inflammation & Immunology Phase:Registration Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: JAK Inhibitor | Ankylosing Spondylitis (U.S., E.U.) | Registration | Product Enhancement | Small Molecule |
ritlecitinib (PF-06651600) Therapeutic Area: Inflammation & Immunology Phase:Phase 3 Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: JAK3/TEC Inhibitor | Alopecia Areata (BREAKTHROUGH) | Phase 3 | New Molecular Entity | Small Molecule |
ritlecitinib +/- PF-06650833; ritlecitinib + PF-06650833 + tofacitinib Therapeutic Area: Inflammation & Immunology Phase:Phase 2 Compound Type:Small Molecule Business Segment: WRDM Mechanism of Action: JAK3/TEC Inhibitor + IRAK4 Inhibitor + JAK Inhibitor | Rheumatoid Arthritis | Phase 2 | New Molecular Entity | Small Molecule |
brepocitinib (PF-06700841) Therapeutic Area: Inflammation & Immunology Phase:Phase 2 Compound Type:Small Molecule Business Segment: WRDM Mechanism of Action: Topical TYK2/JAK1 Inhibitor | Atopic Dermatitis | Phase 2 | New Molecular Entity | Small Molecule |
brepocitinib (PF-06700841) Therapeutic Area: Inflammation & Immunology Phase:Phase 2 Compound Type:Small Molecule Business Segment: WRDM Mechanism of Action: Topical TYK2/JAK1 Inhibitor | Psoriasis | Phase 2 | New Molecular Entity | Small Molecule |
brepocitinib (PF-06700841) Therapeutic Area: Inflammation & Immunology Phase:Phase 2 Compound Type:Small Molecule Business Segment: WRDM Mechanism of Action: TYK2/JAK1 Inhibitor | Psoriatic Arthritis | Phase 2 | Product Enhancement | Small Molecule |
brepocitinib (PF-06700841) Therapeutic Area: Inflammation & Immunology Phase:Phase 2 Compound Type:Small Molecule Business Segment: WRDM Mechanism of Action: TYK2/JAK1 Inhibitor | Alopecia Areata | Phase 2 | Product Enhancement | Small Molecule |
brepocitinib (PF-06700841) Therapeutic Area: Inflammation & Immunology Phase:Phase 2 Compound Type:Small Molecule Business Segment: WRDM Mechanism of Action: TYK2/JAK1 Inhibitor | Lupus | Phase 2 | Product Enhancement | Small Molecule |
Dekavil Therapeutic Area: Inflammation & Immunology Phase:Phase 2 Compound Type:Biologic Business Segment: WRDM Mechanism of Action: IL-10 | Rheumatoid Arthritis (Biologic) | Phase 2 | New Molecular Entity | Biologic |
Eucrisa (crisaborole) Therapeutic Area: Inflammation & Immunology Phase:Phase 2 Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: PDE4 Inhibitor | Stasis Dermatitis | Phase 2 | Product Enhancement | Small Molecule |
PF-06480605 Therapeutic Area: Inflammation & Immunology Phase:Phase 2 Compound Type:Biologic Business Segment: WRDM Mechanism of Action: TNFSF15 Blocker | Ulcerative Colitis (Biologic) | Phase 2 | New Molecular Entity | Biologic |
PF-06650833+ brepocitinib (PF-06700841) + PF-06826647 Therapeutic Area: Inflammation & Immunology Phase:Phase 2 Compound Type:Small Molecule Business Segment: WRDM Mechanism of Action: IRAK4 Inhibitor + TYK2/JAK1 Inhibitor + TYK2 Inhibitor | Hidradenitis Suppurativa | Phase 2 | Product Enhancement | Small Molecule |
PF-06823859 Therapeutic Area: Inflammation & Immunology Phase:Phase 2 Compound Type:Biologic Business Segment: WRDM Mechanism of Action: interferon, beta 1, fibroblast (IFNB1) Blocker | Dermatomyositis (Biologic) (ORPHAN - U.S., E.U., PRIME - E.U.) | Phase 2 | New Molecular Entity | Biologic |
PF-06826647 Therapeutic Area: Inflammation & Immunology Phase:Phase 2 Compound Type:Small Molecule Business Segment: WRDM Mechanism of Action: TYK2 Inhibitor | Psoriasis | Phase 2 | New Molecular Entity | Small Molecule |
PF-07038124 Therapeutic Area: Inflammation & Immunology Phase:Phase 2 Compound Type:Small Molecule Business Segment: WRDM Mechanism of Action: Topical PDE4 Inhibitor | Atopic Dermatitis | Phase 2 | New Molecular Entity | Small Molecule |
ritlecitinib (PF-06651600) + brepocitinib (PF-06700841) Therapeutic Area: Inflammation & Immunology Phase:Phase 2 Compound Type:Small Molecule Business Segment: WRDM Mechanism of Action: JAK3/TECInhibitor + TYK2/JAK1 Inhibitor | Ulcerative Colitis | Phase 2 | New Molecular Entity | Small Molecule |
ritlecitinib (PF-06651600) + brepocitinib (PF-06700841) Therapeutic Area: Inflammation & Immunology Phase:Phase 2 Compound Type:Small Molecule Business Segment: WRDM Mechanism of Action: JAK3/TECInhibitor + TYK2/JAK1 Inhibitor | Crohn's Disease | Phase 2 | Product Enhancement | Small Molecule |
ritlecitinib (PF-06651600) + brepocitinib (PF-06700841) Therapeutic Area: Inflammation & Immunology Phase:Phase 2 Compound Type:Small Molecule Business Segment: WRDM Mechanism of Action: JAK3/TECInhibitor + TYK2/JAK1 Inhibitor | Vitiligo | Phase 2 | Product Enhancement | Small Molecule |
PF-07242813 Therapeutic Area: Inflammation & Immunology Phase:Phase 1 Compound Type:Biologic Business Segment: WRDM Mechanism of Action: CD1a inhibitor | Atopic Dermatitis (Biologic) | Phase 1 | New Molecular Entity | Biologic |
PF-06835375 Therapeutic Area: Inflammation & Immunology Phase:Phase 1 Compound Type:Biologic Business Segment: WRDM Mechanism of Action: Chemokine Inhibitor | Lupus (Biologic) | Phase 1 | New Molecular Entity | Biologic |
PF-07054894 Therapeutic Area: Inflammation & Immunology Phase:Phase 1 Compound Type:Small Molecule Business Segment: WRDM Mechanism of Action: CCR6 Antagonist | Inflammatory Bowel Disease | Phase 1 | New Molecular Entity | Small Molecule |
![iStock-1199449498_380x300[1].jpg](https://cdn.pfizer.com/pfizercom/styles/style_300_170/s3/2021-09/iStock-1199449498_380x300%5B1%5D.jpg?pYyJpQdhyvaU22v13JPyau8ro2rGk0CR&itok=pJGCW7Vt)
